ASYMCHEM LAB.(TIAN.)H YC1 (7K90) - Total Liabilities
Based on the latest financial reports, ASYMCHEM LAB.(TIAN.)H YC1 (7K90) has total liabilities worth €2.74 Billion EUR (≈ $3.21 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 7K90 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
ASYMCHEM LAB.(TIAN.)H YC1 - Total Liabilities Trend (2021–2025)
This chart illustrates how ASYMCHEM LAB.(TIAN.)H YC1's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 7K90 total assets.
ASYMCHEM LAB.(TIAN.)H YC1 Competitors by Total Liabilities
The table below lists competitors of ASYMCHEM LAB.(TIAN.)H YC1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BizConf Telecom Co Ltd
SHE:300578
|
China | CN¥141.93 Million |
|
Guangzhou Jiacheng
SHG:603535
|
China | CN¥2.34 Billion |
|
Deutsche Pfandbriefbank AG
XETRA:PBB
|
Germany | €36.56 Billion |
|
Hebei Gongda Keya Energy Technology Co. Ltd. A
SHE:301197
|
China | CN¥339.40 Million |
|
Eson Precision Ind Co Ltd
TW:5243
|
Taiwan | NT$5.47 Billion |
|
Zhengyuan Geomatics Group Co Ltd
SHG:688509
|
China | CN¥1.89 Billion |
|
Integra Resources Corp
V:ITR
|
Canada | CA$147.99 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down ASYMCHEM LAB.(TIAN.)H YC1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ASYMCHEM LAB.(TIAN.)H YC1 balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ASYMCHEM LAB.(TIAN.)H YC1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ASYMCHEM LAB.(TIAN.)H YC1 (2021–2025)
The table below shows the annual total liabilities of ASYMCHEM LAB.(TIAN.)H YC1 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €2.63 Billion ≈ $3.08 Billion |
+8.46% |
| 2024-12-31 | €2.43 Billion ≈ $2.84 Billion |
+7.48% |
| 2023-12-31 | €2.26 Billion ≈ $2.64 Billion |
-11.28% |
| 2022-12-31 | €2.54 Billion ≈ $2.97 Billion |
-0.08% |
| 2021-12-31 | €2.55 Billion ≈ $2.98 Billion |
-- |
About ASYMCHEM LAB.(TIAN.)H YC1
Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, incl… Read more